Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

(2020) Dejka M. Araujo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

(2020) Matthew D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

(2020) David A. Palma et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases

(2020) Chad G. Rusthoven et al.   JAMA Oncology

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade

(2020) Kathryn C. Arbour et al.   Cancer Discovery

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

(2019) Alessio Cortellini et al.   OncoTargets and Therapy

Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management

(2019) Chiara Casadei et al.   Future Oncology

Treatment sequencing in metastatic colorectal cancer

(2019) D.P. Modest et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy

(2019) Yong Song et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

(2019) Eiji Oki et al.   BRITISH JOURNAL OF CANCER

Real-world treatment patterns and clinical outcomes among patients with advanced melanoma

(2019) C. Lance Cowey et al.   MEDICINE

Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients with Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer

(2019) Dung T. Le et al.   Clinical Colorectal Cancer

HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model

(2019) Jeremy L. Warner et al.   JOURNAL OF BIOMEDICAL INFORMATICS

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline

(2019) N. Lynn Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study

(2019) Changxia Shao et al.   Cancer Medicine

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

(2019) Isabelle Ray-Coquard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

(2018) Liz Morrell et al.   BMC HEALTH SERVICES RESEARCH

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

(2018) Irene L. Wapnir et al.   JOURNAL OF CLINICAL ONCOLOGY

Building of profound knowledge

(2018) Stacy Roehrs   Current Problems in Pediatric and Adolescent Health Care

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis

(2018) Alexandra Moran et al.   JOURNAL OF SURGICAL ONCOLOGY

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Getting Rid of Stupid Stuff

(2018) Melinda Ashton   NEW ENGLAND JOURNAL OF MEDICINE

Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy

(2017) Karl Baker et al.   INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Curative, Life‐Extending, and Palliative Chemotherapy: New Outcomes Need New Names

(2017) Alfred I. Neugut et al.   ONCOLOGIST

Palliative chemotherapy: oxymoron or misunderstanding?

(2016) EJ Roeland et al.   BMC Palliative Care

Guidelines for determination of the number of prior lines of therapy in multiple myeloma

(2015) S. V. Rajkumar et al.   BLOOD

Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

(2015) M. Bonotto et al.   ONCOLOGIST

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes

(2012) Dietrich Pfeiffer et al.   BJU INTERNATIONAL

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER